A Single-blinded Randomized, Placebo-controlled, Staggered-parallel, Escalating-dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injections of GSK 716155 in Subjects With Type 2 Diabetes Mellitus

GlaxoSmithKline1 site in 1 country60 target enrollmentFebruary 2006

ConditionsDiabetes Mellitus, Type 2

InterventionsGSK716155 subcutaneous injections placebo injection

DrugsGSK716155 subcutaneous injections

Overview

Phase: Phase 2
Intervention: GSK716155 subcutaneous injections
Conditions: Diabetes Mellitus, Type 2
Sponsor: GlaxoSmithKline
Enrollment: 60
Locations: 1
Primary Endpoint: blood plasma levels of GSK716155
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus to assess safety and tolerability parameters, the levels of GSK716155 in the bloodstream when it is given at the same dose 7 days apart, and the impact this medication has on various substances in the blood. Assessments include ECGs, vital signs, repeat blood sampling and monitoring of any side effects.

Registry

clinicaltrials.gov

Start Date

February 2006

End Date

September 2006

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel